GlassScriptPhysician profile
Lazaro Cueto
NPI 1750057345
$1,296.27
in general payments reported to CMS, 2019-2025
29 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.65 · 2022: $183 · 2023: $367 · 2024: $382 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,091.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $139.00 | 2024-2025 | Prolate, Nalocet, Tanlor |
| Scilex Pharmaceuticals INC. | $136.38 | 2022-2025 | Ztlido |
| Abbvie INC. | $127.45 | 2023-2025 | |
| Lundbeck LLC | $89.18 | 2023-2025 | Vyepti |
| Globus Medical, INC. | $79.76 | 2025 | Senza, Vyrsa V1 |
| Biotronik Nro, INC. | $65.79 | 2023 | Biotronik |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.53 | 2022-2025 | Relistor |
| Emd Serono, INC. | $64.11 | 2022-2024 | Mavenclad |
| Medtronic, INC. | $57.31 | 2025 | Inceptiv |
| Alexion Pharmaceuticals, INC. | $54.37 | 2023-2024 | Ultomiris |
| Merz Pharmaceuticals, LLC | $48.40 | 2023-2024 | Xeomin |
| Vertos Medical, INC. | $37.11 | 2024 | Mild Device Kit |
| Si-Bone, INC. | $32.29 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.21 | 2023 | |
| Genentech USA, INC. | $23.84 | 2024 | Ocrevus, Enspryng |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $22.65 | 2021 | |
| Appliedvr INC | $21.81 | 2025 | Relievrx |
| Impel Pharmaceuticals INC. | $20.61 | 2022 | |
| Neuronetics, INC. | $19.44 | 2023 | Neurostar Tms Therapy System |
| Argenx US, INC. | $19.26 | 2022 | |
| Celgene Corporation | $19.24 | 2024 | Zeposia |
| Nalu Medical, INC. | $17.52 | 2025 | Nalu Neurostimulation System |
| Upsher-Smith Laboratories LLC | $17.09 | 2023 | |
| Ibsa Pharma INC. | $16.33 | 2023 | Tirosint, Licart |
| Painteq LLC | $16.20 | 2024 | Painteq |
| Averitas Pharma INC. | $15.54 | 2023 | Qutenza |
| Protega Pharmaceutials INC | $15.47 | 2025 | Roxybond |
| Spr Therapeutics, INC | $14.82 | 2024 | Sprint Pns System |
| Curonix LLC | $13.56 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lazaro Cueto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.